The Cooper Companies Inc.
Cooper Companies Reports Strong Q1 2025 Results with Revenue and Earnings Growth
Summary
The Cooper Companies, Inc. reported robust financial results for its fiscal first quarter ended January 31, 2025. The company saw a 4% year-over-year increase in total revenue to $964.7 million, driven by growth in both CooperVision and CooperSurgical segments. GAAP diluted earnings per share (EPS) increased by $0.11 to $0.52, while non-GAAP diluted EPS rose by $0.07 to $0.92. The company also updated its fiscal year 2025 financial guidance, raising its non-GAAP diluted EPS guidance to a range of $3.94 - $4.02.
Profitelligence Alerts
Get alerts for COO
Be first to know when The Cooper Companies Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About The Cooper Companies Inc.
The Cooper Companies Inc. is a global healthcare company that specializes in the production of medical devices, prominently focusing on contact lenses and women's health products. As a key player in the healthcare market, Cooper Companies owns two primary business units: CooperVision and CooperSurgical. CooperVision is renowned for its comprehensive range of soft contact lenses, catering to various vision correction needs such as astigmatism, presbyopia, and myopia control. Meanwhile, CooperSurgical provides innovative products and services focused on women's health, from fertility and lab solutions to surgical tools for gynecological procedures. This diversified business model allows Cooper Companies to impact multiple facets of the healthcare industry, supporting healthcare professionals and enhancing patient care. Headquartered in San Ramon, California, The Cooper Companies is significant in advancing optical technologies and essential medical devices, exemplifying growth within the global healthcare and medical device sectors.
Official SEC Documents
Advertisement